Over the course of the past twelve months the Acorn Regulatory pharmaceutical division has worked on projects in more than 70 countries around the world. In that time they have also taken time out to write some very well received articles that have been read thousands of times. These are the 5 most read articles in 2017 from the Acorn Regulatory pharmaceutical team.
The Falsified Medicines Directive was published in 2011 with the aim of preventing falsified medicines from entering the pharmaceutical supply chain in the European Economic Area.
The falsification of medicines has long been a problem. In recent years the issue has escalated despite the best efforts of agencies such as Medi-Fake. As such, there has been a need to introduce a stronger legislative framework to combat the growth of the problem. The Falsified Medicines Directive (FMD) has been in place since 2013 and companies have been required to implement aspects of the directive since then. Complete conformity with the Falsified Medicines Directive will be required from February 9th 2019. Read more here.
The WDA process is complex. Indeed, many companies turn to us to manage the application process on their behalf. Here, we have highlighted 5 steps that companies must undertake if they want to secure a Wholesale Distribution Authorisation licence. Read more here.
In this article we look at the five things that you need to know when considering virtual wholesaling. Read more here.
In this article we look at the issues surrounding the code of practice that governs pharmaceutical companies in the UK or Ireland. The IPHA and ABPI codes cover the promotion of medicines for prescribing to both health professionals and other relevant decision makers. Read more here.
Every day we are presented with many different types of labels; from the laundry instructions included on clothing labels to nutritional information on food and drink packaging, labels are all around us. So what do these different types of label have in common? They all aim to provide us with information about the associated product. Read more here.
If you would like to talk to us about your regulatory affairs requirements then simply contact us by using the form below or call us on 00353 52 61 76 706.